search
Back to results

68Ga-citrate PET/CT for the Diagnosis of Chronic Prosthetic Hip or Knee Infection (Gal-I-TEP)

Primary Purpose

Prosthetic Joint Infection

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
68Ga-citrate PET/CT
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Prosthetic Joint Infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient referred to the South-Western France referral center for complex bone and joint infections (Crioac GSO, infectious diseases and orthopedic surgery units) for suspicion of first episode of prosthetic hip or knee infection.
  • Suspicion of prosthetic joint infection evolving for more than one month.
  • Patient for who routine diagnosis includes both bone scintigraphy and leukocytes scintigraphy.
  • Patient with positive bone scintigraphy.
  • Being affiliated to a health insurance system
  • Having signed an informed consent form (later than the day of inclusion and before any examination required by the research)

Exclusion Criteria:

  • Patient with active cancer.
  • Patient with negative bone scintigraphy.
  • Patient who cannot stop antibiotics 14 days before exams.
  • Pregnant or breastfeeding women.
  • Women of childbearing age but not using effective means of contraception.
  • Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
  • Subject in relative exclusion period from another study protocol.
  • Known contraindications to PET exam with radiopharmaceutical injection (hypersensitivity to radiopharmaceutical and/or to excipients).

Sites / Locations

  • CHU de Bordeaux - service de maladies infectieusesRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

68Ga-citrate PET/CT

Arm Description

Outcomes

Primary Outcome Measures

Diagnostic accuracy of 68Ga citrate PET / CT scan CT for chronic prosthetic hip or knee infection
Sensibility, specificity, positive and negative predictive value. Index test : 68Ga citrate PET / CT scan CT at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. After 12 months, participants will be considered free of chronic prosthetic hip or knee infection.

Secondary Outcome Measures

Diagnostic accuracy of quantitative 68Ga citrate PET / CT scan for chronic prosthetic hip or knee infection
Area under ROC curve (AUROC) for SUVmax ROI and SUVmax ROI/SVmax liver region ratio measured at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion.
Inter-observer reproducibility of 68Ga-citrate PET/CT interpretation
Intraclass correlation coefficient and/or Cohen's Kappa.
Diagnostic accuracy of leukocyte scintigraphy for chronic prosthetic hip or knee infection
Sensibility, specificity, positive and negative predictive values. Index test : leukocytes scintigraphy at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion.
Diagnosis accuracy of 68Ga-citrate PET/CT and leukocytes scintigraphy for chronic prosthetic hip or knee infection in the following sub-groups: prosthetic knee or hip infection.
Sensibility, specificity, positive and negative predictive values, in each subgroup. Index test : 68Ga citrate PET / CT scan CT at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. After 12 months, participants will be considered free of chronic prosthetic hip or knee infection.
Comparison of diagnostic accuracy of 68Ga-PET/CT and leukocytes scintigraphy for chronic prosthetic hip or knee infection
Sensibility, specificity, positive and negative predictive values. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. Index test : 68Ga citrate PET / CT scan CT at inclusion and leukocytes scintigraphy at inclusion.

Full Information

First Posted
June 16, 2021
Last Updated
January 20, 2023
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT04938193
Brief Title
68Ga-citrate PET/CT for the Diagnosis of Chronic Prosthetic Hip or Knee Infection
Acronym
Gal-I-TEP
Official Title
68Gallium-citrate Positron Emission Tomography/Computed Tomography (68Ga-citrate PET/CT) for the Diagnosis of Chronic Prosthetic Hip or Knee Infection
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 2, 2022 (Actual)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
February 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Diagnosis of chronic prosthetic joint infection (PJI) can be difficult. 68Ga-citrate Positron Emission Tomography/Computed Tomography (PET/CT) has been recently developed and has many advantages such as high resolution and low radiation exposure. To date, 68Ga-citrate PET/CT has not been specifically assessed in prosthetic joint infection. In this prospective study, patients referred for a suspected PJI will benefit from both a 68Ga-citrate PET/CT and a 99mTc-HMPAO-labelled leukocyte SPECT/CT. The primary outcome is the assessment of the 68Ga-citrate PET/CT accuracy for the diagnosis of chronic prosthetic hip or knee infection.
Detailed Description
Prosthetic joint infection (PJI) is a serious and rare complication of orthopedic surgery. Diagnosis is based on precise criteria (MSIS criteria Musculoskeletal Infection Society). However, diagnosis can be difficult, in particular when the infection is present for more than one month. One of the usual exams is bone scintigraphy and 99mTc-HMPAO-labelled leukocyte scintigraphy. This imaging allows an accurate assessment but it has some limitations since it requires ex vivo isolation and marking of patient's leukocytes and repeated acquisition for 24 hours. 68Gallium-citrate positron emission tomography/computed tomography (68Ga-citrate PET/CT) has been recently developed. 68Ga-citrate PET/CT is innovative compared to [18F]fluorodeoxyglucose PET/CT (18F-FDG PET/CT) and has many advantages: high resolution, realization in only two hours, short radioactive period and no handling of patient's leukocytes. Furthermore, preliminary data indicate that 68Ga-citrate is picked up by immune cells, which makes this exam inflammation-selective. To date, 68Ga-citrate PET/CT has not been specifically assessed in PJI, it is the objective of the present study: Prospective study using 68Ga- citrate PET/CT and a 99mTc-HMPAO-labelled leukocyte SPECT/CT. Patients referred for a suspected PJI and with a positive bone scintigraphy will be prospectively enrolled. After information and signature of informed consent, patients will benefit from a 68Ga citrate PET/CT, in addition to leukocyte scintigraphy in a two-week period. Both images will be anonymized and interpreted by two independent nuclear physicians. Final PJI diagnosis is based on reference criteria (MSIS) to ensure diagnosis during the standardized medical follow-up. Patients will be followed until 12 months after the leukocyte scintigraphy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prosthetic Joint Infection

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
68Ga-citrate PET/CT
Arm Type
Experimental
Intervention Type
Diagnostic Test
Intervention Name(s)
68Ga-citrate PET/CT
Intervention Description
PET/CT Imaging with 68Ga-citrate PET/CT injection
Primary Outcome Measure Information:
Title
Diagnostic accuracy of 68Ga citrate PET / CT scan CT for chronic prosthetic hip or knee infection
Description
Sensibility, specificity, positive and negative predictive value. Index test : 68Ga citrate PET / CT scan CT at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. After 12 months, participants will be considered free of chronic prosthetic hip or knee infection.
Time Frame
Up to 12 months after baseline (Day 0)
Secondary Outcome Measure Information:
Title
Diagnostic accuracy of quantitative 68Ga citrate PET / CT scan for chronic prosthetic hip or knee infection
Description
Area under ROC curve (AUROC) for SUVmax ROI and SUVmax ROI/SVmax liver region ratio measured at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion.
Time Frame
Up to 12 months after baseline (Day 0)
Title
Inter-observer reproducibility of 68Ga-citrate PET/CT interpretation
Description
Intraclass correlation coefficient and/or Cohen's Kappa.
Time Frame
Up to 12 months after baseline (Day 0)
Title
Diagnostic accuracy of leukocyte scintigraphy for chronic prosthetic hip or knee infection
Description
Sensibility, specificity, positive and negative predictive values. Index test : leukocytes scintigraphy at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion.
Time Frame
Up to 12 months after baseline (Day 0)
Title
Diagnosis accuracy of 68Ga-citrate PET/CT and leukocytes scintigraphy for chronic prosthetic hip or knee infection in the following sub-groups: prosthetic knee or hip infection.
Description
Sensibility, specificity, positive and negative predictive values, in each subgroup. Index test : 68Ga citrate PET / CT scan CT at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. After 12 months, participants will be considered free of chronic prosthetic hip or knee infection.
Time Frame
Up to 12 months after baseline (Day 0)
Title
Comparison of diagnostic accuracy of 68Ga-PET/CT and leukocytes scintigraphy for chronic prosthetic hip or knee infection
Description
Sensibility, specificity, positive and negative predictive values. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. Index test : 68Ga citrate PET / CT scan CT at inclusion and leukocytes scintigraphy at inclusion.
Time Frame
Up to 12 months after baseline (Day 0)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient aged over 18 years old Patient referred for the first time to the South-Western France referral center for complex bone and joint infections (Crioac GSO, infectious diseases and orthopedic surgery units) for suspicion of prosthetic hip or knee infection. Suspicion of prosthetic joint infection evolving for more than one month. Patient for who routine diagnosis includes both bone scintigraphy and leukocytes scintigraphy. Patient with positive bone scintigraphy. Being affiliated to a health insurance system Having signed an informed consent form (later than the day of inclusion and before any examination required by the research) Exclusion Criteria: Patient with active cancer. Patient with negative bone scintigraphy. Patient who cannot stop antibiotics 14 days before exams. Pregnant or breastfeeding women. Women of childbearing age but not using effective means of contraception. Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent). Subject in relative exclusion period from another study protocol. Known contraindications to PET exam with radiopharmaceutical injection (hypersensitivity to radiopharmaceutical and/or to excipients).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Frédéric-Antoine DAUCHY, MD
Phone
05 56 79 55 36
Ext
+33
Email
frederic.dauchy@chu-bordeaux.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Pauline PERREAU
Email
pauline.perreau@chu-bordeaux.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frédéric-Antoine DAUCHY, MD
Organizational Affiliation
CHU Bordeaux
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eric FRISON, MD
Organizational Affiliation
CHU Bordeaux
Official's Role
Study Chair
Facility Information:
Facility Name
CHU de Bordeaux - service de maladies infectieuses
City
Bordeaux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric-Antoine DAUCHY, MD
Email
frederic.dauchy@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Pauline PERREAU
Email
pauline.perreau@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Frédéric-Antoine DAUCHY, MD
First Name & Middle Initial & Last Name & Degree
Julie LEITAO, MD
First Name & Middle Initial & Last Name & Degree
Henri DE CLERMONT-GALLERANDE, MD
First Name & Middle Initial & Last Name & Degree
Nicolas BALAMOUTOFF, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

68Ga-citrate PET/CT for the Diagnosis of Chronic Prosthetic Hip or Knee Infection

We'll reach out to this number within 24 hrs